/PTCT
PTCT Stock - PTC Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$78.57+5.34%
+$3.98 (+5.34%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.95
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).43
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-3.5%upside
Target: $75.82
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PTCT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$77.78 – $79.36
TARGET (TP)$75.80
STOP LOSS$72.28
RISK/REWARD1:-0.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.47
52W High$87.50
52W Low$35.95
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $806.78M | $937.82M | $698.80M | $538.59M | $380.77M |
| Gross Profit | $749.38M | $872.34M | $654.12M | $506.26M | $361.82M |
| Gross Margin | 92.9% | 93.0% | 93.6% | 94.0% | 95.0% |
| Operating Income | $-302,570,000 | $-439,502,000 | $-447,409,000 | $-374,443,000 | $-431,768,000 |
| Net Income | $-363,295,000 | $-626,604,000 | $-559,017,000 | $-523,901,000 | $-438,160,000 |
| Net Margin | -45.0% | -66.8% | -80.0% | -97.3% | -115.1% |
| EPS | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 |
Company Overview
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
47%
Hold / Neutral
5
33%
Sell / Underperform
3
20%
Analyst Consensus🔴 Bearish
7 Bullish8 Neutral/Bearish
Price Targets
$52
Average Target
↓ 34.1% Downside
Now
$17
Low
$52
Average
$91
High
Based on 21 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 1st 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $91 |
| October 20th 2025 | Wells Fargo | Initiation | Overweight | $73 |
| June 17th 2025 | Truist | Initiation | Buy | $80 |
| May 9th 2025 | BofA Securities | Upgrade | Buy | $68 |
| May 7th 2025 | Citigroup | Upgrade | Neutral | $40 |
| March 11th 2025 | BofA Securities | Upgrade | Neutral | $55← $41 |
| March 7th 2025 | Scotiabank | Initiation | Sector Perform | $55 |
| December 13th 2024 | Morgan Stanley | Upgrade | Overweight | $67← $45 |
| December 3rd 2024 | RBC Capital Mkts | Upgrade | Outperform | $63← $39 |
| October 10th 2024 | Raymond James | Resumed | Market Perform | - |
| September 4th 2024 | Robert W. Baird | Initiation | Outperform | $44 |
| August 26th 2024 | UBS | Resumed | Buy | $47 |
| May 20th 2024 | Raymond James | Upgrade | Market Perform | - |
| December 19th 2023 | Morgan Stanley | Downgrade | Underweight | $28 |
| December 8th 2023 | Wells Fargo | Initiation | Overweight | $37 |
Earnings History & Surprises
PTCTBeat Rate
39%
Last 18 quarters
Avg Surprise
+43.6%
EPS vs Estimate
Beats / Misses
7/11
Last 12 quarters
Latest EPS
$0.20
Q4 2025
EPS Surprise History
Q1 24
-182.8%
$-0.24vs$0.29
Q2 24
+0.8%
$-1.20vs$-1.21
Q3 24
-16.0%
$-1.16vs$-1.00
Q4 24
+9.7%
$-1.39vs$-1.54
Q1 25
+78.6%
$-0.24vs$-1.12
Q2 25
+1029.6%
$10.04vs$-1.08
Q3 25
+22.4%
$-0.83vs$-1.07
Q4 25
+116.8%
$0.20vs$-1.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.97 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-1.19 | $0.20 | +116.8% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-1.07 | $-0.83 | +22.4% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-1.08 | $10.04 | +1029.6% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-1.12 | $-0.24 | +78.6% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-1.54 | $-1.39 | +9.7% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.00 | $-1.16 | -16.0% | ✗ MISS |
Q2 2024 | Apr 25, 2024 | $-1.21 | $-1.20 | +0.8% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $0.29 | $-0.24 | -182.8% | ✗ MISS |
Q4 2023 | Oct 26, 2023 | $-0.85 | $-1.76 | -107.1% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-1.58 | $-2.66 | -68.4% | ✗ MISS |
Q2 2023 | Apr 27, 2023 | $-1.64 | $-1.88 | -14.6% | ✗ MISS |
Q1 2023 | Feb 21, 2023 | $-1.96 | $-2.35 | -19.9% | ✗ MISS |
Q4 2022 | Oct 27, 2022 | $-1.37 | $-1.53 | -11.7% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-1.67 | $-2.13 | -27.5% | ✗ MISS |
Q2 2022 | May 3, 2022 | $-1.55 | $-1.78 | -14.8% | ✗ MISS |
Q1 2022 | Feb 22, 2022 | $-1.79 | $-2.03 | -13.4% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $-1.78 | $-1.89 | -6.2% | ✗ MISS |
Q3 2021 | Jul 29, 2021 | $-1.84 | $-1.68 | +8.7% | ✓ BEAT |
Latest News
PTC Therapeutics Canada Says Health Canada Approves Sephience For Treatment Of Children And Adults Living With Phenylketonuria
📈 PositiveBenzinga•Dec 10, 2025, 01:09 PM
RBC Capital Downgrades PTC Therapeutics to Sector Perform, Raises Price Target to $91
➖ NeutralBenzinga•Dec 1, 2025, 02:22 PM
S&P Small Cap 600 Constituent Sandisk Corp. Will Replace The Interpublic Group Of Companies Inc. In The S&P 500, And PTC Therapeutics Inc. Will Replace Sandisk In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Friday, November 28
📈 PositiveBenzinga•Nov 24, 2025, 10:22 PM•Also: , ,
Barclays Maintains Equal-Weight on PTC Therapeutics, Raises Price Target to $68
➖ NeutralBenzinga•Nov 6, 2025, 03:00 PM•Also:
Citigroup Maintains Neutral on PTC Therapeutics, Raises Price Target to $75
➖ NeutralBenzinga•Nov 5, 2025, 08:43 PM•Also:
TD Cowen Maintains Hold on PTC Therapeutics, Raises Price Target to $63
➖ NeutralBenzinga•Nov 5, 2025, 06:47 PM
RBC Capital Maintains Outperform on PTC Therapeutics, Raises Price Target to $82
📈 PositiveBenzinga•Nov 5, 2025, 05:12 PM
Goldman Sachs Maintains Sell on PTC Therapeutics, Raises Price Target to $50
➖ NeutralBenzinga•Nov 5, 2025, 04:57 PM
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $93
📈 PositiveBenzinga•Nov 5, 2025, 03:11 PM
PTC Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance.
📈 PositiveBenzinga•Nov 4, 2025, 09:45 PM
PTC Therapeutics Raises FY2025 Sales Guidance from $650.000M-$800.000M to $750.000M-$800.000M vs $1.733B Est
📉 NegativeBenzinga•Nov 4, 2025, 09:03 PM
PTC Therapeutics Q3 EPS $0.20 Beats $(1.42) Estimate, Sales $211.007M Beat $185.251M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:02 PM
Jefferies Maintains Buy on PTC Therapeutics, Raises Price Target to $77
📈 PositiveBenzinga•Oct 28, 2025, 06:54 PM•Also:
Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $118 Price Target
📈 PositiveBenzinga•Sep 3, 2025, 01:49 PM
Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $73
➖ NeutralBenzinga•Aug 20, 2025, 06:42 PM•Also:
Morgan Stanley Maintains Overweight on PTC Therapeutics, Lowers Price Target to $71
➖ NeutralBenzinga•Aug 20, 2025, 03:53 PM•Also:
B of A Securities Maintains Buy on PTC Therapeutics, Lowers Price Target to $76
➖ NeutralBenzinga•Aug 20, 2025, 12:21 PM•Also:
Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Aug 19, 2025, 12:25 PM
PTC Therapeutics Receives Complete Response Letter From The FDA Regarding Its NDA For Vatiquinone
📉 NegativeBenzinga•Aug 19, 2025, 12:03 PM
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Aug 19, 2025, 11:55 AM
Frequently Asked Questions about PTCT
What is PTCT's current stock price?
PTC Therapeutics, Inc. (PTCT) is currently trading at $78.57 per share. The stock has moved +5.34% today.
What is the analyst price target for PTCT?
The average analyst price target for PTCT is $75.80, based on 1 analyst.
What sector is PTC Therapeutics, Inc. in?
PTC Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PTCT's market cap?
PTC Therapeutics, Inc. has a market capitalization of $6.31 billion, making it a mid-cap company.
Does PTCT pay dividends?
No, PTC Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACLX
Arcellx, Inc.
$63.96
Mkt Cap: $3.5B
ALKS
Alkermes plc
$28.45
Mkt Cap: $4.7B
ARWR
Arrowhead Pharmaceuticals, Inc.
$68.16
Mkt Cap: $9.4B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
KRYS
Krystal Biotech, Inc.
$240.80
Mkt Cap: $7.0B
MTSR
Metsera, Inc.
$70.50
Mkt Cap: $7.4B
PCVX
Vaxcyte, Inc.
$46.42
Mkt Cap: $6.1B
PTGX
Protagonist Therapeutics, Inc.
$86.05
Mkt Cap: $5.4B
RNA
Avidity Biosciences, Inc.
$72.34
Mkt Cap: $9.5B
TGTX
TG Therapeutics, Inc.
$30.98
Mkt Cap: $4.9B
Explore stocks similar to PTCT for comparison